Mucocutaneous Lymph Node Syndrome - 25 Studies Found
Completed |
: Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease : Kawasaki Disease : 2008-09-25 :
|
Completed |
: Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 : Kawasaki Disease : 2014-12-08 |
Recruiting |
: A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease : Kawasaki Disease : 2016-10-28 :
|
Withdrawn |
: Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease : Kawasaki Disease : 2016-10-24 : Drug: Canakinumab Other Name: ACZ885 |
Recruiting |
: Etiology Study of Kawasaki Disease : Kawasaki Disease : 2005-09-09 |
Completed |
: Infliximab (Remicade) for Patients With Acute Kawasaki Disease : Kawasaki Disease : 2005-12-30 :
|
Completed |
: Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease : Kawasaki Disease : 2012-01-25 : Drug: immunoglobulin G Intravenously administer a single dose of the product (2g/kg) for at least 12 hou |
Completed |
: A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease : Kawasaki Disease : 2005-09-09 : Drug: Sestamibi Sestamibi Other Name: Cardiolite |
Completed |
: Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease : Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin : 2012-05-09 :
|
Recruiting |
: Anakinra and Kawasaki Disease :
: 2015-03-11 : Drug: Anakinra The dose of Anakinra will be 2mg/kg. If the patient remains febrile (fever >38°C) |